Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer
Drug guidance

Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer

Condition

Cancer

Gynaecological

16 September 2025

-

Published on 16 Sep 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended durvalumab in combination with platinum-based chemotherapy, then as maintenance with or without olaparib, for inclusion on the MOH List of Subsidised Drugs for patients with untreated primary advanced or recurrent endometrial cancer. The decision was based on the uncertainties surrounding the magnitude of clinical benefit compared with chemotherapy, and unfavourable cost-effectiveness compared with chemotherapy and dostarlimab.

Clinical indication, subsidy class and MediShield Life claim limit for durvalumab and olaparib are provided in the Annex.

Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer (Uploaded 16 Sep 2025) [PDF, 254 KB]

PES Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer (Uploaded 16 Sep 2025) [PDF, 103 KB]

Back to top